Literature DB >> 16231313

Limitations with the response evaluation criteria in solid tumors (RECIST) guidance in disseminated pediatric malignancy.

A M Barnacle1, Kieran McHugh.   

Abstract

BACKGROUND: Response evaluation criteria in solid tumors (RECIST) guidelines were published in 2000 to evaluate response to treatment in solid tumors. These have sought to unify response assessment, and the new guidelines extend beyond lesion assessment to address modern imaging strategies. The RECIST guidelines, however, become complex and problematic when used to evaluate metastatic disease.
METHODS: Ten consecutive oncology cases representative of tumors common to our pediatric practice were selected. All cases were evaluated at initial presentation and follow-up. The RECIST criteria were retrospectively applied in each case. A standardized evaluation form was used.
RESULTS: The age range of the patients included in the study was 1 month to 16 years, with a mean age of 3.9 years. A range of tumor responses was identified: partial response (n = 6), stable disease (n = 2), and progressive disease (n = 2). Two of these responses were likely incorrect. Tumor bulk was underestimated in the axial plane, many lesions were either calcified and unmeasurable, or despite being well-defined were too small to be measurable under the strict RECIST guidance.
CONCLUSION: In highlighting specific problems with disseminated pediatric tumors, we emphasize the pressing need for debate regarding the application of RECIST in pediatric oncology and encourage the development of a pediatric radiology oncology group to collaborate in future modifications of the RECIST guidance.

Entities:  

Mesh:

Year:  2006        PMID: 16231313     DOI: 10.1002/pbc.20344

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  14 in total

Review 1.  Imaging-based tumor treatment response evaluation: review of conventional, new, and emerging concepts.

Authors:  Hee Kang; Ho Yun Lee; Kyung Soo Lee; Jae-Hun Kim
Journal:  Korean J Radiol       Date:  2012-06-18       Impact factor: 3.500

2.  The ALARA concept in pediatric oncology.

Authors:  Stephan D Voss; Gregory H Reaman; Sue C Kaste; Thomas L Slovis
Journal:  Pediatr Radiol       Date:  2009-09-30

Review 3.  The role of (18)F-FDG positron emission tomography in the follow-up of liver tumors treated with (90)Yttrium radioembolization.

Authors:  Oreste Bagni; Luca Filippi; Orazio Schillaci
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-02-15

Review 4.  Pediatric oncology and the future of oncological imaging.

Authors:  Stephan D Voss
Journal:  Pediatr Radiol       Date:  2011-04-27

5.  Molecular response assessed by (68)Ga-DOTANOC and survival after (90)Y microsphere therapy in patients with liver metastases from neuroendocrine tumours.

Authors:  Luca Filippi; Francesco Scopinaro; Giuseppe Pelle; Roberto Cianni; Rita Salvatori; Orazio Schillaci; Oreste Bagni
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-02       Impact factor: 9.236

Review 6.  From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.

Authors:  Richard L Wahl; Heather Jacene; Yvette Kasamon; Martin A Lodge
Journal:  J Nucl Med       Date:  2009-05       Impact factor: 10.057

Review 7.  Imaging in unilateral Wilms tumour.

Authors:  Hervé J Brisse; Anne M Smets; Sue C Kaste; Catherine M Owens
Journal:  Pediatr Radiol       Date:  2007-11-16

8.  Objective assessment of tumour response to therapy based on tumour growth kinetics.

Authors:  E Mehrara; E Forssell-Aronsson; P Bernhardt
Journal:  Br J Cancer       Date:  2011-07-26       Impact factor: 7.640

Review 9.  Imaging biomarkers for evaluating tumor response: RECIST and beyond.

Authors:  Ching-Chung Ko; Lee-Ren Yeh; Yu-Ting Kuo; Jeon-Hor Chen
Journal:  Biomark Res       Date:  2021-07-02

Review 10.  Imaging findings in noncraniofacial childhood rhabdomyosarcoma.

Authors:  Rick R Van Rijn; Jim C H Wilde; Johannes Bras; Foppe Oldenburger; Kieran M C McHugh; Johannes H M Merks
Journal:  Pediatr Radiol       Date:  2008-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.